Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.
Chaganti S, Maycock S, McIlroy G, Jackson AE, Bishop R, Johnson S, Kanfer E, Kassam S, Cwynarski K, Wrench DJ, Arumainathan A, Fox CP, Johnson RJ, McKay P, Paneesha S, Rowntree C, Balotis C, Collins GP, Davies AJ, Wright J, Burns S Dr, Laurence ADJ, Wheatley K, Menne T. Chaganti S, et al. Blood. 2024 Apr 21:blood.2024023847. doi: 10.1182/blood.2024023847. Online ahead of print. Blood. 2024. PMID: 38643491
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Chaganti S, Smith J, Chau I, Culligan D, Linton KM, Collins GP, Ferreri AJM, Lewis D, Davies AJ, Johnson R, Auer DP, Cwynarski K. Fox CP, et al. Among authors: chaganti s. Blood Adv. 2021 Oct 26;5(20):4073-4082. doi: 10.1182/bloodadvances.2021004779. Blood Adv. 2021. PMID: 34464973 Free PMC article. Clinical Trial.
Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
Burns DM, Clesham K, Hodgson YA, Fredrick L, Haughton J, Lannon M, Hussein H, Shin JS, Hollows RJ, Robinson L, Byrne C, McNamara C, Vydianath B, Lennard AL, Fields P, Johnson R, Wright J, Fox CP, Cwynarski K, Chaganti S. Burns DM, et al. Among authors: chaganti s. Transplantation. 2020 Dec;104(12):2582-2590. doi: 10.1097/TP.0000000000003183. Transplantation. 2020. PMID: 33104308
Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.
Burns DM, Tierney R, Shannon-Lowe C, Croudace J, Inman C, Abbotts B, Nagra S, Fox CP, Chaganti S, Craddock CF, Moss P, Rickinson AB, Rowe M, Bell AI. Burns DM, et al. Among authors: chaganti s. Blood. 2015 Dec 17;126(25):2665-75. doi: 10.1182/blood-2015-08-665000. Epub 2015 Oct 8. Blood. 2015. PMID: 26450987 Free PMC article.
Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline.
Shah N, Eyre TA, Tucker D, Kassam S, Parmar J, Featherstone C, Andrews P, Asgari E, Chaganti S, Menne TF, Fox CP, Pettit S, Suddle A, Bowles KM; Haemato-Oncology Task Force of the British Society for Haematology and the British Transplantation Society. Shah N, et al. Among authors: chaganti s. Br J Haematol. 2021 May;193(4):727-740. doi: 10.1111/bjh.17421. Epub 2021 Apr 20. Br J Haematol. 2021. PMID: 33877688 No abstract available.
Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.
Poynton E, Chernucha E, Day J, Prodger C, Hopkins D, Rakesh P, O'Neill T, Thakrar N, Akarca A, Jamal E, Ali A, Kirkwood AA, Pomplun S, Marafioti T, Calaminici M, Greaves P, Chaganti S, McKay P, Smith J, Eyre TA, Martinez-Calle N, Cwynarski K, Fox CP, Okosun J. Poynton E, et al. Among authors: chaganti s. Blood Adv. 2024 Apr 9;8(7):1772-1775. doi: 10.1182/bloodadvances.2023011426. Blood Adv. 2024. PMID: 38039509 Free PMC article. No abstract available.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O'Reilly M, Norman J, Osborne W, Bloor A, Lugthart S, Malladi R, Patten PEM, Neill L, Martinez-Cibrian N, Kennedy H, Phillips EH, Jones C, Sharplin K, El-Sharkawi D, Latif AL, Mathew A, Uttenthal B, Stewart O, Marzolini MAV, Townsend W, Cwynarski K, Ardeshna K, Ardavan A, Robinson K, Pagliuca A, Collins GP, Johnson R, McMillan A. Kuhnl A, et al. Among authors: chaganti s. Br J Haematol. 2022 Aug;198(3):492-502. doi: 10.1111/bjh.18209. Epub 2022 Apr 29. Br J Haematol. 2022. PMID: 35485402
Management of secondary central nervous system lymphoma.
Cwynarski K, Cummin T, Osborne W, Lewis J, Chaganti S, Smith J, Linton K, Greaves P, McKay P, Fox CP; British Society for Haematology (BSH) Committee. Cwynarski K, et al. Among authors: chaganti s. Br J Haematol. 2023 Jan;200(2):160-169. doi: 10.1111/bjh.18539. Epub 2022 Nov 21. Br J Haematol. 2023. PMID: 36408800 No abstract available.
155 results